Advertisement

Infection

pp 1–6 | Cite as

GeneXpert of stool versus gastric lavage fluid for the diagnosis of pulmonary tuberculosis in severely ill adults

  • Rongmei Liu
  • Qian Liang
  • Yuanyuan Shang
  • Yifeng Ma
  • Fen Wang
  • Lingling Dong
  • Hairong HuangEmail author
  • Mengqiu GaoEmail author
  • Yu PangEmail author
Original Paper
  • 72 Downloads

Abstract

Purpose

Stool is an alternative specimen matrix for tuberculosis (TB) tests, because Mycobacterium tuberculosis (MTB) can be swallowed and detected in the samples from digestive tract. We aimed to assess the performance of GeneXpert on stool and gastric lavage fluid (GALF) in diagnosing TB among patients with severe pulmonary TB.

Methods

We enrolled adults with suspected pulmonary TB who were unable to produce sputum at visit between January 2016 and June 2018. Bacteriological samples consisted of one transtracheal aspirate sputum specimen, one stool specimen and/or one gastric lavage fluid specimen. Bacterial culture of transtracheal aspirate sputum provided the gold standard.

Results

Of 65 individuals recruited for analysis, MGIT culture identified the presence of MTB in 32 samples. Overall, 29 of 32 stool samples from culture-positive cases were detected by the GeneXpert test, demonstrating a sensitivity of 90.6%. For GALF, 13 patients were detected as infected with MTB by GeneXpert, yielding a sensitivity of 56.5%. The statistical analysis revealed that GeneXpert showed significantly better sensitivity in detecting MTB from stool samples than GALF samples (P = 0.003). Among individuals with GeneXpert-positive stool, the percentage of individuals with comorbid diabetes was significantly higher than among individuals with GeneXpert-negative stool (19.4% vs. 2.9%, P = 0.034).

Conclusions

In conclusion, our data reveal that GeneXpert provides a higher detection rate on stool compared to GALF, indicating stool should be considered as an alternative for adult TB patients unable to produce sputum. Individuals with diabetes are more likely to have positive GeneXpert stool than nondiabetic individuals.

Keywords

Mycobacterium tuberculosis Severe tuberculosis Stool GeneXpert 

Notes

Acknowledgements

We would like to thank members of the National Tuberculosis Reference Laboratory at the Chinese Center for Disease Control and Prevention for their technical assistance.

Funding

This work was supported by the Beijing Municipal Administration of Hospitals’ Youth Programme (QML20171601), and the Chinese Clinical Trial Cooperation Support Programme (2018KYJJ002).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This study was approved by the Ethic Committee of Beijing Chest Hospital affiliated to Capital Medical University. Written informed consent was obtained from the immediate relative on behalf of each patient.

References

  1. 1.
    World Health Organization. Global tuberculosis report 2017. Geneva: WHO 2017; 2017 (WHO/HTM/TB/2017.13).Google Scholar
  2. 2.
    Tan Y, Su B, Zheng H, Wang Y, Pang Y. Prothionamide susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTECMGIT 960 system. Eur J Clin Microbiol Infect Dis. 2017;36:779–82.CrossRefGoogle Scholar
  3. 3.
    Nahid P, Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc. 2006;3:103–10.CrossRefGoogle Scholar
  4. 4.
    Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis. 2015;211:21-8.CrossRefGoogle Scholar
  5. 5.
    Aslam W, Tahseen S, Schomotzer C, Hussain A, Khanzada F, Ul Haq M, et al. Gastric specimens for diagnosing tuberculosis in adults unable to expectorate in Rawalpindi, Pakistan. Public Health Action. 2017;7:141–6.CrossRefGoogle Scholar
  6. 6.
    Pang Y, Wang Y, Zhao S, Liu J, Zhao Y, Li H. Evaluation of the Xpert MTB/RIF assay in gastric lavage aspirates for diagnosis of smear-negative childhood pulmonary tuberculosis. Pediatr Infect Dis J. 2014;33:1047–51.CrossRefGoogle Scholar
  7. 7.
    Larson JL, Ridzon R, Hannan MM. Sputum induction versus fiberoptic bronchoscopy in the diagnosis of tuberculosis. Am J Respir Crit Care Med. 2001;163:1279–80.CrossRefGoogle Scholar
  8. 8.
    Ruiz Jimenez M, Guillen Martin S, Prieto Tato LM, Cacho Calvo JB, Alvarez Garcia A, Soto Sanchez B, et al. Induced sputum versus gastric lavage for the diagnosis of pulmonary tuberculosis in children. BMC Infect Dis. 2013;13:222.CrossRefGoogle Scholar
  9. 9.
    Wolf H, Mendez M, Gilman RH, Sheen P, Soto G, Velarde AK, et al. Diagnosis of pediatric pulmonary tuberculosis by stool PCR. Am J Trop Med Hyg. 2008;79:893–8.CrossRefGoogle Scholar
  10. 10.
    Cordova J, Shiloh R, Gilman RH, Sheen P, Martin L, Arenas F, et al. Evaluation of molecular tools for detection and drug susceptibility testing of Mycobacterium tuberculosis in stool specimens from patients with pulmonary tuberculosis. J Clin Microbiol. 2010;48:1820–6.CrossRefGoogle Scholar
  11. 11.
    Walters E, van der Zalm MM, Palmer M, Bosch C, Demers AM, Draper H, et al. Xpert MTB/RIF on stool is useful for the rapid diagnosis of tuberculosis in young children with severe pulmonary disease. Pediatr Infect Dis J. 2017;36:837–43.CrossRefGoogle Scholar
  12. 12.
    World Health Organization. Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children, WHO Policy update. Geneva: WHO 2014; 2014. (WHO/HTM/TB/2013.16).Google Scholar
  13. 13.
    Orikiriza P, Nansumba M, Nyehangane D, Bastard M, Mugisha IT, Nansera D, et al. Xpert MTB/RIF diagnosis of childhood tuberculosis from sputum and stool samples in a high TB-HIV-prevalent setting. Eur J Clin Microbiol Infect Dis. 2018.Google Scholar
  14. 14.
    Tan Y, Li Q, Wang Q, Sun H, Chen J, Cai X, et al. Evaluation of the MTBDRplus 2.0 assay for the detection of multidrug resistance among persons with presumptive pulmonary TB in China. Sci Rep. 2017;7:3364.CrossRefGoogle Scholar
  15. 15.
    Rahman SMM, Maliha UT, Ahmed S, Kabir S, Khatun R, Shah JA, et al. Evaluation of Xpert MTB/RIF assay for detection of Mycobacterium tuberculosis in stool samples of adults with pulmonary tuberculosis. PLoS One. 2018;13:e0203063.CrossRefGoogle Scholar
  16. 16.
    Nicol MP, Spiers K, Workman L, Isaacs W, Munro J, Black F, et al. Xpert MTB/RIF testing of stool samples for the diagnosis of pulmonary tuberculosis in children. Clin Infect Dis. 2013;57:e18–21.CrossRefGoogle Scholar
  17. 17.
    Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol. 2010;48:2495–501.CrossRefGoogle Scholar
  18. 18.
    Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152.CrossRefGoogle Scholar
  19. 19.
    Podell BK, Ackart DF, Obregon-Henao A, Eck SP, Henao-Tamayo M, Richardson M, et al. Increased severity of tuberculosis in Guinea pigs with type 2 diabetes: a model of diabetes-tuberculosis comorbidity. Am J Pathol. 2014;184:1104–18.CrossRefGoogle Scholar
  20. 20.
    Ronacher K, Joosten SA, van Crevel R, Dockrell HM, Walzl G, Ottenhoff TH. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev. 2015;264:121–37.CrossRefGoogle Scholar
  21. 21.
    Banada PP, Naidoo U, Deshpande S, Karim F, Flynn JL, O’Malley M, et al. A novel sample processing method for rapid detection of tuberculosis in the stool of pediatric patients using the Xpert MTB/RIF assay. PLoS One. 2016;11:e0151980.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Tuberculosis Department, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest HospitalCapital Medical UniversityBeijingPeople’s Republic of China
  2. 2.Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest HospitalCapital Medical UniversityBeijingChina

Personalised recommendations